NASDAQ:MGX Metagenomi (MGX) Stock Price, News & Analysis $1.91 -0.14 (-6.83%) Closing price 04:00 PM EasternExtended Trading$1.95 +0.04 (+2.09%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Metagenomi Stock (NASDAQ:MGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Metagenomi alerts:Sign Up Key Stats Today's Range$1.90▼$2.0850-Day Range$1.85▼$3.7952-Week Range$1.61▼$11.86Volume246,656 shsAverage Volume1.05 million shsMarket Capitalization$71.48 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingModerate Buy Company OverviewMetagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Read More… Remove Ads Metagenomi Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreMGX MarketRank™: Metagenomi scored higher than 36% of companies evaluated by MarketBeat, and ranked 734th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingMetagenomi has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMetagenomi has received no research coverage in the past 90 days.Read more about Metagenomi's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Metagenomi are expected to decrease in the coming year, from ($2.46) to ($2.52) per share.Read more about Metagenomi's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.11% of the float of Metagenomi has been sold short.Short Interest Ratio / Days to CoverMetagenomi has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Metagenomi has recently increased by 3.11%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMetagenomi does not currently pay a dividend.Dividend GrowthMetagenomi does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.11% of the float of Metagenomi has been sold short.Short Interest Ratio / Days to CoverMetagenomi has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Metagenomi has recently increased by 3.11%, indicating that investor sentiment is decreasing. News and Social Media2.2 / 5News Sentiment0.93 News SentimentMetagenomi has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Metagenomi this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for MGX on MarketBeat in the last 30 days. This is a decrease of -96% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Metagenomi to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Metagenomi insiders have not sold or bought any company stock.Read more about Metagenomi's insider trading history. Receive MGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metagenomi and its competitors with MarketBeat's FREE daily newsletter. Email Address MGX Stock News HeadlinesMetagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) SystemsMarch 13 at 6:19 AM | globenewswire.comThis Emirati Prince Controls Four Times Elon Musk's Wealth and He’s Going All-In on AIFebruary 27, 2025 | msn.comDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.March 13, 2025 | Altimetry (Ad)Metagenomi to Present at TD Cowen's 45th Annual Health Care ConferenceFebruary 11, 2025 | globenewswire.comTotus Medicines Appoints Simon Harnest As CFOJanuary 28, 2025 | markets.businessinsider.comNeutral On Metagenomi's Promising Yet Highly Speculative Gene Editing PotentialJanuary 28, 2025 | seekingalpha.comPromising Outlook for Metagenomi, Inc.: Strategic Collaborations and Technological Advancements Drive Buy RatingJanuary 17, 2025 | markets.businessinsider.comMetagenomi advances gene editing therapies into 2025January 16, 2025 | msn.comSee More Headlines MGX Stock Analysis - Frequently Asked Questions How have MGX shares performed this year? Metagenomi's stock was trading at $3.61 on January 1st, 2025. Since then, MGX shares have decreased by 47.1% and is now trading at $1.91. View the best growth stocks for 2025 here. When did Metagenomi IPO? Metagenomi (MGX) raised $94 million in an initial public offering (IPO) on Friday, February 9th 2024. The company issued 6,250,000 shares at a price of $15.00 per share. Who are Metagenomi's major shareholders? Metagenomi's top institutional shareholders include Geode Capital Management LLC (1.57%), Norges Bank (0.96%), Peapod Lane Capital LLC (0.94%) and Pura Vida Investments LLC (0.71%). Insiders that own company stock include Holdings A/S Novo and Pamela Wapnick. View institutional ownership trends. How do I buy shares of Metagenomi? Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Metagenomi own? Based on aggregate information from My MarketBeat watchlists, some other companies that Metagenomi investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Today3/13/2025Next Earnings (Estimated)3/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MGX Previous SymbolNASDAQ:MGX CIK1785279 Webwww.metagenomi.co Phone510-871-4880FaxN/AEmployees236Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$17.00 Low Stock Price Target$6.00 Potential Upside/Downside+571.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,250,000.00 Net Margins-134.27% Pretax Margin-137.13% Return on Equity-43.23% Return on Assets-18.86% Debt Debt-to-Equity RatioN/A Current Ratio6.18 Quick Ratio6.18 Sales & Book Value Annual Sales$55.08 million Price / Sales1.31 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares37,424,000Free FloatN/AMarket Cap$72.42 million OptionableN/A BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free Report This page (NASDAQ:MGX) was last updated on 3/13/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.